U.S. FDA approves Amylyx ALS drug




  • In US
  • 2022-09-29 20:45:08Z
  • By Reuters
 

(Reuters) -The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

The Amylyx drug, to be sold under the brand name Relyvrio, is a combination of the generic compounds sodium phenylbutyrate and taurursodiol. The company says they work together to prevent nerve cells in the brain and spinal cord from dying prematurely.

ALS, also known as Lou Gehrig's disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. It affects more than 30,000 patients in the United States, according to patient advocacy group The ALS Association.

Amylyx's case for approval was built on a recent analysis of clinical trial data that it said showed the drug slows progression of the disease and extends life expectancy by nearly 10 months.

The FDA's decision follows an approval recommendation from an outside panel of advisers in a rare reversal. The agency reconvened the panel in September to look at the new data analyses after it had previously recommended against approving the drug in March.

Shares of the drugmaker were up nearly 7% in extended trading following the approval.

(Reporting by Leroy Leo and Bhanvi Satija in Bengaluru; editing by Caroline Humer, Bill Berkrot and Krishna Chandra Eluri)

COMMENTS

More Related News

U.S. FDA declines to approve Y-mAbs
U.S. FDA declines to approve Y-mAbs's pediatric cancer drug

Y-mAbs said it is assessing the implications of the Food and Drug Administration's complete response letter (CRL) and the company's plans for the drug's development program. The FDA's decision follows a unanimous vote by its advisers in October against the drug, omburtamab, to treat neuroblastoma due to insufficient evidence that it improves overall survival. "We are disappointed but not surprised based on the outcome of the (FDA advisory panel) meeting," interim Chief Executive Officer Thomas Gad said in a statement.

U.S. FDA approves Rigel Pharma
U.S. FDA approves Rigel Pharma's treatment for a type of leukemia

The Food and Drug Administration approved the drug, which will be sold under the brand Rezlidhia, for the treatment of a type of cancer of the blood and bone marrow called acute myeloid leukemia in patients with a susceptible genetic mutation. Approval for the oral drug was supported by data from the company's mid-stage study, which showed a 35% rate for complete remission of the cancer with a complete or partial recovery in blood count. Rezlidhia will be the company's second treatment to get approval from the FDA after Tavalisse for a rare bleeding disorder called immune thrombocytopenic purpura.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US